22 October 2021 - Company voluntarily withdraws biologics license application at FDA’s recommendation following full approval of pembrolizumab, which came four months earlier than FDA goal date.

 Agenus today announced a strategic decision to withdraw its biologics license application for balstilimab, its PD-1 inhibitor. The decision to withdraw the biologics license application does not change the development plans for balstilimab combinations.

Read Agenus press release